CRSP Crispr Therapeutics AG
Company Analysis
Latest News
🔴 Crispr Therapeutics is trading 4.8% down today amid broader risk-off pressure on growth biotech shares
Crispr Therapeutics is trading at $56.66 with a -4.77% change (about 4.8% lower) during early trading on August 24, 2026, amid broader risk-off pressure on...
🟢 Crispr Therapeutics is trading 6.05% up today amid possible delayed reaction to August 3 earnings
Crispr Therapeutics is trading 6.05% up at $61.63, with no new company-specific announcement identified for August 21, 2026; the gain appears driven by...
🔴 Crispr Therapeutics falls 4.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Crispr Therapeutics is trading 10.01% up today after positive Phase 3 melanoma cancer-vaccine results
Crispr Therapeutics is trading at $58.27, +10.01% on August 19, 2026, as biotechnology shares rally after Moderna and Merck reported positive Phase 3 melanoma...
🟢 Crispr Therapeutics is trading 6.21% up today after Moderna’s positive Phase 3 cancer-vaccine results
Crispr Therapeutics is trading 6.21% up at $56.26, benefiting primarily from strong biotech-sector momentum rather than a new company-specific announcement. -...
🔴 Crispr Therapeutics is trading 4.3% down today amid broad market pullback
Crispr Therapeutics is trading 4.3% down at $51.95, amid a broad market pullback. - The Nasdaq Composite is down 1.42% and the S&P 500 is down 0.67%, with...
🟢 Crispr Therapeutics is trading 4.1% up today on weak July jobs data and rate-cut hopes
Crispr Therapeutics is trading 4.1% up at $53.78, supported primarily by a broader biotech rally and renewed risk appetite after unexpectedly weak July...
🟢 Crispr Therapeutics is trading 4.1% up today after Q2 earnings beat and CASGEVY label expansion
Crispr Therapeutics is trading 4.1% up at $51.59 after reporting second-quarter results that beat revenue and EPS expectations, driven by rapid CASGEVY launch...
CRISPR Therapeutics' second quarter revenue and EPS beat expectations, driven by strong CASGEVY sales growth.
CRISPR Therapeutics reported second quarter 2026 total revenue of $10.2 million and a net loss of $0.94 per share, beating analyst estimates for both metrics....
Crispr Therapeutics AG Q2 2026 Earnings Preview: What Analysts Expect on August 03, 2026
Crispr Therapeutics is expected to report a Q2 2026 loss of $1.10 per share on revenue of $7.11 million, with the stock currently trading at $47.53 against an...
🔴 Crispr Therapeutics is trading 4.6% down today amid ongoing biotech sector weakness
Crispr Therapeutics is trading at $49.00 (down 4.6%) as the stock continues a multi-day slide driven by broader biotech sector headwinds and valuation...
🔴 Crispr Therapeutics is trading 4% down today amid valuation debates and profit-taking in high-beta biotech
Crispr Therapeutics is trading at $51.21 (4% down) as its multi-day slide continues following recent valuation debates and profit-taking in high-beta...
🔴 Crispr Therapeutics is trading 5.3% down today as multi-day decline extends on valuation concerns
Crispr Therapeutics is trading at $53.34 (5.3% down) as the stock extends a multi-day decline following recent CASGEVY label expansion headlines and mixed...
🔴 Crispr Therapeutics is trading 4.2% down today as shares pull back on mixed valuation sentiment
Crispr Therapeutics is trading 4.2% down now at $56.72 as shares continue to pull back following recent CASGEVY label expansion headlines and mixed sentiment...
🔴 CRSP Slips 4.1% Despite FDA Label Expansion for CASGEVY and Analyst Buy Reiteration
CRSP is trading 4.1% down today at $58.31, pulling back from its recent rally. This comes despite H.C. Wainwright reiterating a Buy rating and an $80 price...
🔴 CRSP is trading 4.3% down today amid a pullback from its recent rally
CRSP is trading 4.3% down at $59.22 today as the stock pulls back from its recent rally amid mixed broader market action. • The move appears to be normal...
CRISPR and Vertex Win FDA Approval for Casgevy, Adding 5,500 Patients
The U.S. Food and Drug Administration expanded approval for Casgevy to include children aged two and older. CRISPR Therapeutics and Vertex Pharmaceuticals...
🟢 CRSP extends move to 5.4% up
CRSP is trading at $58.64, up 5.4% versus the comparison close of $55.62 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 CRSP is trading 4.58% up today on analyst optimism and pipeline progress
CRSP is trading at $58.17 (+4.58%) as bullish analyst sentiment and pipeline progress continue to support the stock. Recent coverage highlighted repeated...
🟢 CRSP is trading 4.3% up today on analyst optimism and pipeline progress
CRSP is trading 4.3% up at $56.88 today, extending gains as the stock continues to benefit from recent positive sentiment among Wall Street analysts. • The...